Machine learning-based prediction of drug-drug interactions by integrating drug phenotypic, therapeutic, chemical, and genomic properties.
暂无分享,去创建一个
[1] D. Hosmer,et al. Applied Logistic Regression , 1991 .
[2] J. Ross Quinlan,et al. C4.5: Programs for Machine Learning , 1992 .
[3] Alberto Maria Segre,et al. Programs for Machine Learning , 1994 .
[4] D. Bates,et al. Systems analysis of adverse drug events. ADE Prevention Study Group. , 1995, JAMA.
[5] N. Dickey,et al. Systems analysis of adverse drug events. , 1996, JAMA.
[6] Sanjay Gupta,et al. Olanzapine Augmentation of Clozapine , 1998, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.
[7] M. Heo,et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. , 1999, The American journal of psychiatry.
[8] I. Edwards,et al. Adverse drug reactions: definitions, diagnosis, and management , 2000, The Lancet.
[9] Pierre Baldi,et al. Assessing the accuracy of prediction algorithms for classification: an overview , 2000, Bioinform..
[10] P. Shannon,et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.
[11] S. Stahl. Describing an Atypical Antipsychotic: Receptor Binding and Its Role in Pathophysiology , 2003 .
[12] S. Tsai,et al. Severe Cardiovascular Side Effects of Olanzapine in an Elderly Patient: Case Report , 2003, International journal of psychiatry in medicine.
[13] A. Laupacis,et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. , 2003, JAMA.
[14] Corinna Cortes,et al. Support-Vector Networks , 1995, Machine Learning.
[15] L. Wienkers,et al. Predicting in vivo drug interactions from in vitro drug discovery data , 2005, Nature Reviews Drug Discovery.
[16] R. Kerwin,et al. Management of clozapine-resistant schizophrenia , 2005 .
[17] Peter Willett,et al. Similarity-based virtual screening using 2D fingerprints. , 2006, Drug discovery today.
[18] M. Thase,et al. Bipolar Depression: Best Practices for the Hospitalized Patient , 2007, CNS Spectrums.
[19] Charles B. Nemeroff,et al. Antidepressant Drug-Drug Interactions: Clinical Relevance and Risk Management , 2007, CNS Spectrums.
[20] L J Lesko,et al. Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling , 2007, Clinical pharmacology and therapeutics.
[21] H. Nasrallah,et al. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles , 2008, Molecular Psychiatry.
[22] Paul Watson,et al. Naïve Bayes Classification Using 2D Pharmacophore Feature Triplet Vectors , 2008, J. Chem. Inf. Model..
[23] Ruili Huang,et al. Comprehensive Characterization of Cytochrome P450 Isozyme Selectivity across Chemical Libraries , 2009, Nature Biotechnology.
[24] Chitta Baral,et al. Discovering drug–drug interactions: a text-mining and reasoning approach based on properties of drug metabolism , 2010, Bioinform..
[25] P. Bork,et al. A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.
[26] Michael Schroeder,et al. SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions , 2009, Nucleic Acids Res..
[27] Lei Yang,et al. Classification of Cytochrome P450 Inhibitors and Noninhibitors Using Combined Classifiers , 2011, J. Chem. Inf. Model..
[28] Chih-Jen Lin,et al. LIBSVM: A library for support vector machines , 2011, TIST.
[29] Yue Yu,et al. In silico prediction of Tetrahymena pyriformis toxicity for diverse industrial chemicals with substructure pattern recognition and machine learning methods. , 2011, Chemosphere.
[30] David S. Wishart,et al. DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..
[31] F. Cheng,et al. Insights into Molecular Basis of Cytochrome P450 Inhibitory Promiscuity of Compounds , 2011, J. Chem. Inf. Model..
[32] Chris Morley,et al. Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.
[33] Thomas C. Wiegers,et al. The Comparative Toxicogenomics Database: update 2011 , 2010, Nucleic Acids Res..
[34] Yoshihiro Yamanishi,et al. Drug target prediction using adverse event report systems: a pharmacogenomic approach , 2012, Bioinform..
[35] Chuang Liu,et al. Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference , 2012, PLoS Comput. Biol..
[36] Carol Friedman,et al. Drug-drug interaction through molecular structure similarity analysis , 2012, J. Am. Medical Informatics Assoc..
[37] Russ B. Altman,et al. A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports , 2012, J. Am. Medical Informatics Assoc..
[38] Hua Xu,et al. Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs , 2012, J. Am. Medical Informatics Assoc..
[39] R. Sharan,et al. INDI: a computational framework for inferring drug interactions and their associated recommendations , 2012, Molecular systems biology.
[40] Hua Xu,et al. DTome: a web-based tool for drug-target interactome construction , 2012, BMC Bioinformatics.
[41] Yadi Zhou,et al. Prediction of chemical-protein interactions: multitarget-QSAR versus computational chemogenomic methods. , 2012, Molecular bioSystems.
[42] Yang Song,et al. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery , 2011, Nucleic Acids Res..
[43] Xu Han,et al. Literature Based Drug Interaction Prediction with Clinical Assessment Using Electronic Medical Records: Novel Myopathy Associated Drug Interactions , 2012, PLoS Comput. Biol..
[44] Charlotte Harrison. GlaxoSmithKline opens the door on clinical data sharing , 2012, Nature Reviews Drug Discovery.
[45] Guixia Liu,et al. Performance Evaluation of 2D Fingerprint and 3D Shape Similarity Methods in Virtual Screening , 2012, J. Chem. Inf. Model..
[46] R. Altman,et al. Data-Driven Prediction of Drug Effects and Interactions , 2012, Science Translational Medicine.
[47] Yadi Zhou,et al. Prediction of Chemical-Protein Interactions Network with Weighted Network-Based Inference Method , 2012, PloS one.
[48] Thomas C. Wiegers,et al. The Comparative Toxicogenomics Database: update 2013 , 2012, Nucleic Acids Res..
[49] Jie Shen,et al. Adverse Drug Events: Database Construction and in Silico Prediction , 2013, J. Chem. Inf. Model..
[50] Feixiong Cheng,et al. In silico ADMET prediction: recent advances, current challenges and future trends. , 2013, Current topics in medicinal chemistry.
[51] Ruth Nussinov,et al. Structure and dynamics of molecular networks: A novel paradigm of drug discovery. A comprehensive review , 2012, Pharmacology & therapeutics.
[52] M. Dickinson,et al. Coronary Microvascular Pericytes Are the Cellular Target of Sunitinib Malate–Induced Cardiotoxicity , 2013, Science Translational Medicine.
[53] R. Altman,et al. Informatics confronts drug-drug interactions. , 2013, Trends in pharmacological sciences.
[54] Jie Li,et al. Prediction of Polypharmacological Profiles of Drugs by the Integration of Chemical, Side Effect, and Therapeutic Space , 2013, J. Chem. Inf. Model..
[55] Ben Y. Reis,et al. Pharmacointeraction Network Models Predict Unknown Drug-Drug Interactions , 2013, PloS one.
[56] Hongkang Mei,et al. Systematic Prediction of Pharmacodynamic Drug-Drug Interactions through Protein-Protein-Interaction Network , 2013, PLoS Comput. Biol..
[57] George Papadatos,et al. The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..